title: New drugs 09, part 2.
authors.affiliation: Philadelphia College of Pharmacy, University of Sciences in Philadelphia, Pa., USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D054179:Angioedemas, Hereditary / Q000188:drug therapy; D001565:Benzoates / Q000627:therapeutic use; D002352:Carrier Proteins / Q000627:therapeutic use; D003174:Complement C1 Inactivator Proteins / Q000627:therapeutic use; D050718:Complement C1 Inhibitor Protein; D017277:Drug Approval; D004358:Drug Therapy / Q000451:nursing* / Q000639:trends*; D064420:Drug-Related Side Effects and Adverse Reactions; D005477:Fluprednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D006834:Hydrazines / Q000627:therapeutic use; D007634:Keratitis / Q000188:drug therapy / Q000209:etiology; D024802:Nurse's Role; D013508:Ophthalmologic Surgical Procedures / Q000009:adverse effects; D010149:Postoperative Pain / Q000188:drug therapy / Q000209:etiology; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011961:Receptors, Fc / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D013747:Tetrabenazine / Q000627:therapeutic use; D013926:Thrombopoietin; D014605:Uveitis / Q000188:drug therapy / Q000209:etiology
chemical_list: D018759:Adrenergic Uptake Inhibitors; D001565:Benzoates; D002352:Carrier Proteins; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D006834:Hydrazines; D011720:Pyrazoles; D011725:Pyridines; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; C469952:SERPING1 protein, human; C118563:clevidipine; D013926:Thrombopoietin; D005477:Fluprednisolone; C488777:romiplostim; C520809:eltrombopag; C015808:difluprednate; D013747:Tetrabenazine